Atea Pharmaceuticals, Inc. Stock Price, News & Analysis

Atea Pharmaceuticals has announced new findings published in Nature Communications regarding its antiviral drug bemnifosbuvir (AT-527). The data reveal that bemnifosbuvir's unique dual mechanism targets both chain termination and nucleotidylyltransferase inhibition, which may create a significant barrier to viral resistance. In Phase 2 trials, the drug has shown rapid antiviral activity and is generally safe for high-risk COVID-19 patients. This positions bemnifosbuvir as a promising option for treating COVID-19 and other viral diseases, according to Atea's leadership.

Atea Pharmaceuticals (AVIR) is advancing its clinical development strategy with plans for a global Phase 2 outpatient trial of bemnifosbuvir (AT-527) for COVID-19. The company has also secured exclusive worldwide rights to ruzasvir (RZR) from Merck, aiming to combine it with bemnifosbuvir for hepatitis C treatment. Furthermore, Atea is launching a Phase 2 proof-of-concept program for AT-752 targeting dengue fever. The Phase 2 COVID-19 trial will enroll 200 high-risk outpatients, with topline data expected in late 2022.

Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO and Founder Jean-Pierre Sommadossi will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 8:15 a.m. ET. A live webcast of the presentation will be available on the Company’s website and will remain accessible for 90 days post-event.

Atea focuses on developing oral therapies for life-threatening viral diseases, leveraging its expertise in antiviral drug development and nucleos(t)ide chemistry, targeting viruses like SARS-CoV-2 and hepatitis C.

Atea Pharmaceuticals (Nasdaq: AVIR) announced its inclusion in the NASDAQ Biotech Index, effective December 20, 2021. This addition aims to enhance the company's visibility in the investment community. CEO Jean Pierre Sommadossi emphasized that joining the index will broaden awareness of Atea's mission to develop oral antiviral treatments for severe viral diseases, including COVID-19. The NASDAQ Biotech Index tracks biotechnology and pharmaceutical securities that meet specific eligibility criteria, reinforcing Atea's standing in the biopharmaceutical sector.

Atea Pharmaceuticals (AVIR) has updated its development strategy for AT-527 in response to the evolving SARS-CoV-2 variants and the changing COVID-19 treatment landscape. The company will close the Phase 3 MORNINGSKY trial and amend the ongoing Phase 2 trial for high-risk, unvaccinated outpatients. The strategy emphasizes AT-527's unique dual-target mechanism, enabling its potential as both a monotherapy and a combination therapy. Atea plans to initiate preclinical in vitro combination studies while continuing to leverage internal resources for the development of its antiviral candidates in 2022.

Atea Pharmaceuticals (Nasdaq: AVIR) has announced that its CEO, Jean-Pierre Sommadossi, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 3:05 p.m. ET. A live webcast will be available on the company's website, with a replay offered for 90 days post-event. Atea focuses on developing oral therapies targeting life-threatening viral infections, including SARS-CoV-2, dengue virus, hepatitis C, and respiratory syncytial virus using a proprietary nucleotide prodrug platform.

Atea Pharmaceuticals (NASDAQ: AVIR) announced the termination of its collaboration with Roche for the development of AT-527 for COVID-19, effective February 10, 2022. This change allows Atea to regain full rights for the clinical development and commercialization of AT-527 globally. Atea has $839.7 million in cash, ensuring a runway through 2023. The company is proceeding with the Phase 3 MORNINGSKY trial, expecting results in the second half of 2022, thereby enhancing its autonomy to bring AT-527 to market.

Atea Pharmaceuticals (AVIR) announced key updates in its third quarter 2021 report. A protocol amendment for the Phase 3 MORNINGSKY trial will refine the patient population to unvaccinated high-risk individuals and increase the dosage of AT-527 to 1,100 mg BID. Results from the Phase 2 MOONSONG trial indicated rapid antiviral activity against COVID-19, especially in high-risk patients. Financially, Atea reported collaboration revenue of $32.8 million and a net loss of $28.2 million for the quarter, a significant increase from the prior year's loss. Cash reserves stand at $839.7 million.

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) will host a live conference call on November 11, 2021, at 4:30 p.m. ET to report its third quarter financial results for the period ending September 30, 2021. The company focuses on developing oral therapeutics for life-threatening viral diseases, leveraging a proprietary nucleotide prodrug platform. The call will include a clinical and corporate update, with access details available on Atea's website. A recorded webcast will be archived approximately two hours after the event.